[go: up one dir, main page]

BRPI0903089B8 - recombinant peptides and protein motifs mimetic to leishmania antigens and their applications - Google Patents

recombinant peptides and protein motifs mimetic to leishmania antigens and their applications

Info

Publication number
BRPI0903089B8
BRPI0903089B8 BRPI0903089A BRPI0903089A BRPI0903089B8 BR PI0903089 B8 BRPI0903089 B8 BR PI0903089B8 BR PI0903089 A BRPI0903089 A BR PI0903089A BR PI0903089 A BRPI0903089 A BR PI0903089A BR PI0903089 B8 BRPI0903089 B8 BR PI0903089B8
Authority
BR
Brazil
Prior art keywords
leishmania
protein motifs
mimetic
recombinant peptides
applications
Prior art date
Application number
BRPI0903089A
Other languages
Portuguese (pt)
Inventor
Graci Brito Madurro Ana
Paula Peres Freschi Ana
Roberto Prudêncio Carlos
Emílio Capparelli Fausto
Figueira Messias Flávia
Rocha Lino De Souza Guilherme
Marcos Madurro João
Franco Almeida Juliana
Ricardo Goulart Filho Luiz
Cardoso Rone
Original Assignee
Fund De Amparo A Pesquisa Do Estado De Minas Gerais
Imunoscan Engenharia Molecular Ltda Me
Univ Federal De Uberlandia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund De Amparo A Pesquisa Do Estado De Minas Gerais, Imunoscan Engenharia Molecular Ltda Me, Univ Federal De Uberlandia filed Critical Fund De Amparo A Pesquisa Do Estado De Minas Gerais
Priority to BRPI0903089A priority Critical patent/BRPI0903089B8/en
Publication of BRPI0903089A2 publication Critical patent/BRPI0903089A2/en
Publication of BRPI0903089B1 publication Critical patent/BRPI0903089B1/en
Publication of BRPI0903089B8 publication Critical patent/BRPI0903089B8/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

peptídeos recombinantes e motivos proteicos miméticos a antígenos de leishmania e suas aplicações. a presente invenção refere-se à seleção, caracterização e utilização de peptídeos recombinantes, suas sequências reversas e motivos proteicos que mimetizam regiões antigênicas parciais de proteínas de leíshmania e antígenos de interesse diagnóstico e vacinal para as doenças causadas por parasitos do gênero leishmania. os peptideos objetos desta invenção foram selecionados por "phage display" e são alvos para utilização em imunodiagnósticos e em composições vacinais para o controle dos diferentes tipos de doença provocados pelos parasitos do gênero acima citado por serem especificamente imunorreativos com o soro de indivíduos infectados.recombinant peptides and protein motifs mimetic to leishmania antigens and their applications. the present invention refers to the selection, characterization and use of recombinant peptides, their reverse sequences and protein motifs that mimic partial antigenic regions of leishmania proteins and antigens of diagnostic and vaccine interest for diseases caused by parasites of the leishmania genus. the peptides object of this invention were selected by "phage display" and are targets for use in immunodiagnostics and in vaccine compositions for the control of different types of disease caused by parasites of the aforementioned genus, as they are specifically immunoreactive with the serum of infected individuals.

BRPI0903089A 2009-08-12 2009-08-12 recombinant peptides and protein motifs mimetic to leishmania antigens and their applications BRPI0903089B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0903089A BRPI0903089B8 (en) 2009-08-12 2009-08-12 recombinant peptides and protein motifs mimetic to leishmania antigens and their applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0903089A BRPI0903089B8 (en) 2009-08-12 2009-08-12 recombinant peptides and protein motifs mimetic to leishmania antigens and their applications

Publications (3)

Publication Number Publication Date
BRPI0903089A2 BRPI0903089A2 (en) 2011-04-12
BRPI0903089B1 BRPI0903089B1 (en) 2021-05-18
BRPI0903089B8 true BRPI0903089B8 (en) 2021-05-25

Family

ID=43837853

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0903089A BRPI0903089B8 (en) 2009-08-12 2009-08-12 recombinant peptides and protein motifs mimetic to leishmania antigens and their applications

Country Status (1)

Country Link
BR (1) BRPI0903089B8 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018037343A1 (en) * 2016-08-23 2018-03-01 Universidade Federal De Minas Gerais Vaccine compositions for protecting against visceral leishmaniasis, synthetic peptides and uses
BR102016021357A2 (en) * 2016-09-16 2018-04-03 Universidade Federal De Minas Gerais VACINAL COMPOSITION FOR PROTECTION AGAINST TEGUMENTARY LEISHMANIASIS

Also Published As

Publication number Publication date
BRPI0903089B1 (en) 2021-05-18
BRPI0903089A2 (en) 2011-04-12

Similar Documents

Publication Publication Date Title
ES2558330T3 (en) Peptide WT1 restricted by HLA-A * 3303 and pharmaceutical composition comprising the same
BR112014006376A2 (en) protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
BR112012018951C8 (en) monoclonal antibody, pharmaceutical composition, pharmaceutical combination, use of an antibody, use of a pharmaceutical composition and use of a pharmaceutical combination
BR112022009707A2 (en) TCR PRAME RECEIVERS AND USES THEREOF
BR112014020019A2 (en) recombinant poxviral vectors expressing both rabies and ox40 proteins and vaccines made from these
BR112013008407A2 (en) clostridium difficile antigens
BRPI0707779B8 (en) isolated antigen, vaccine composition and method for producing an antigen protein
BR112013029409A8 (en) improved peptide pharmaceuticals for insulin resistance
BRPI0816784A8 (en) NEURO-ENDOCRINE FACTORS FOR THE TREATMENT OF DEGENERATIVE DISEASES
BR112012005713A2 (en) langerhans cell targeted vaccines.
ECSP11011367A (en) PHARMACEUTICAL COMPOSITION
CR20130016A (en) PEPTIDIC ANTIBODIES BETA AMILOIDE ANTI-N3pGlu AND USES OF THE SAME
BRPI0715396B8 (en) method of producing a vaccine composition
CY1116646T1 (en) ANTI-CANCER Fusion Protein
BR112012022229A2 (en) beta amyloid epitope specific for oligomer and antibodies
BR112014015390A2 (en) vesicular stomatitis virus for initial and booster vaccines
BR112014018884A2 (en) computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
BR112015032556A2 (en) MODIFIED MATRIX PROTEIN (M) FROM A VESICULAR STOMATITIS VIRUS (VSV); NUCLEOTIDE SEQUENCE ENCODING A MODIFIED MATRIX PROTEIN OF A VESICULAR STOMATITIS VIRUS; RECOMBINANT VESICULAR STOMATITIS VIRUS (RVSV); VACCINE; PREPARATION AND BOOST COMBINATION VACCINE; KIT; ISOLATED PEPTIDE; ISOLATED NUCLEOTIDE SEQUENCES; USE OF THE VACCINE; USE OF THE PREPARATION AND BOOST COMBINATION VACCINE; METHOD FOR INDUCING AN IMMUNE RESPONSE IN AN INDIVIDUAL
EA201391200A1 (en) METHODS AND COMPOSITIONS FOR VACCINATION FROM STAPHYLOCOCCUS AUREUS
BR112018012055A2 (en) recombinant transglutaminase (tg) substrate, in vitro method for labeling a protein of interest, pharmaceutical or diagnostic composition and diagnostic kit
MX2011007963A (en) Neil3 peptides and vaccines including the same.
ES2721159T3 (en) Novel MHC-independent tumor associated antigens
BR112015023738B8 (en) INFLUENZA NUCLEOPROTEIN VACCINES
BR112013023978A2 (en) "Heat shock protein affinity polypeptide and its use in the diagnosis of infectious disease, immune response production and treatment of cancer, as well as nucleic acid, substance composition and fractionation method for clinical sample research or analysis."

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/08/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2787 DE 04-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.